A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT05513703 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: Telisotuzumab Vedotin

Sponsor

AbbVie